CTSZ disruptions, compositions and methods relating thereto
OwnerRobert G. Wisotzkey, Christopher J. Kirkinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a CTSZ gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
Claims29
A transgenic mouse comprising a disruption in a CTSZ gene.
A transgenic mouse comprising a disruption in a CTSZ gene, wherein there is no native expression of CTSZ gene.
A method of producing a transgenic mouse comprising a disruption in a CTSZ gene, the method comprising:
- (a) providing a murine stem cell comprising a disruption in a CTSZ gene;
- and
- (b) introducing the murine stem cell into a pseudopregnant mouse, wherein the pseudopregnant mouse gives birth to a transgenic mouse.
A targeting construct comprising:
- (a) a first polynucleotide sequence homologous to at least a first portion of a CTSZ gene;
- (b) a second polynucleotide sequence homologous to at least a second portion of a CTSZ gene;
- and
- (c) a selectable marker.
A cell comprising a disruption in a CTSZ gene.
The cell of claim 15, wherein the embryonic stem cell is a murine cell.
A method of identifying an agent that modulates a symptom associated with rheumatoid arthritis, the method comprising:
- (a) contacting a test agent with CTSZ;
- and
- (b) determining whether the agent modulates CTSZ.
A method of identifying an agent that modulates a symptom associated with inflammatory bowel disease, the method comprising:
- (a) contacting a test agent with a CTSZ;
- and
- (b) determining whether the agent modulates the CTSZ.
A method of identifying an agent for the treatment of rheumatoid arthritis, the method comprising:
- (a) contacting a test agent with CTSZ;
- and
- (b) determining whether the agent modulates CTSZ.
A method of identifying an agent that modulates inflammatory bowel disease, the method comprising:
- (a) contacting a test agent with a CTSZ;
- and
- (b) determining whether the agent modulates the CTSZ molecule.
A method of identifying an agent that modulates a phenotype associated with a disruption in CTSZ, the method comprising:
- (a) administering a test agent to an animal exhibiting the phenotype;
- and
- (b) determining whether the agent modulates the phenotype.
A method of evaluating a potential therapeutic agent capable of affecting a condition associated with CTSZ, the method comprising:
- (a) administering the potential therapeutic agent to a transgenic mouse comprising a disruption in a CTSZ gene;
- and
- (b) evaluating the effects of the agent on the transgenic mouse.
A method of evaluating a potential therapeutic agent capable of affecting a condition associated with CTSZ, the method comprising:
- (a) contacting the potential therapeutic agent with CTSZ;
- (b) evaluating the effects of the agent on the CTSZ.
A therapeutic agent for treating inflammatory bowel disease, wherein the agent modulates CTSZ.
A therapeutic agent for treating rheumatoid arthritis, wherein the agent is an agonist or antagnonist of CTSZ.
A pharmaceutical composition comprising CTSZ.
A method of preparing a pharmaceutical composition for a condition associated with a function of CTSZ, the method comprising:
- (a) identifying a compound that modulates CTSZ;
- (b) synthesizing the identified compound;
- and
- (c) incorporating the compound into a pharmaceutical carrier.
Phenotypic data associated with a transgenic mouse comprising a disruption in a CTSZ gene, wherein the phenotypic data is in an electronic database.
Dependencies are inferred from the claim text.